1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon: International Agency for Research on Cancer. IARC; 2014. Available from:
http://globocan.iarc.fr
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
3. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22(11):1931–43.
4. IARC: Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 91. Lyon: International Agency for Research on Cancer; 2007: 1–528.
5. Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE, Speizer FE, Michels KB. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ health study: prospective cohort study. Bmj. 2014;349:g6356.